Ramos et al. demonstrated the safety and efficacy of CD30 CAR T cells in their Phase I trial of nine patients with relapsed, refractory, heavily pre-treated Hodgkin lymphoma (HL) and EBV negative, CD30+ ALCL. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.